RecruitingNCT06616714

Faesiblity and Safety of Endoscopic sLeeve gastrOplasty in Patients With obEsity and nflammatoRy Bowel Disease

Faesiblity and Safety of Endoscopic sLeeve gastrOplasty in Patients With obEsity and inflammatoRy Bowel Disease

Sponsor

Laterza Lucrezia

Enrollment

20 participants

Start Date

May 20, 2024

Study Type

OBSERVATIONAL

Conditions

Obesity Inflammatory Bowel Diseases

Summary

Obesity is classified as a body mass index (BMI) above 30 kg/m2 by the World Health Organization. Both overweight (BMI \> 25 kg/m2) and obesity (BMI \>30 kg/m2) have increased worldwide during the last decades: 1.46 billion of the adult population were estimated to be overweight in 2008, particularly 205 million men and 297 millions of women were estimated to be obese. Obesity is associated with lower quality of life and is linked to serious comorbidities such as type 2 diabetes mellitus, hypertension, cardiovascular diseases and several cancers. Furthermore, obesity is significantly linked to a higher mortality risk compared to normal weight individuals. Obesity is also significantly increasing in patients with IBD. Obesity enhances the inflammatory activity in IBD, leads to longer hospitalization, and increases the possibility to develop extra intestinal manifestations. Also, the frequency of having extended systemic steroid treatment and use of antibiotics seems greater in IBD patients with obesity. Hence, treatment and prevention of obesity, especially in IBD patients, should have high priority.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Inclusion Criteria6

Age 18 to 70 years
BMI between 30 to 40 kg/m2
Willingness to participate in the study and ability to comply and understand the study protocol
Patients with steroid-free clinical remission of IBD for at least 6 months before screening as defined by HBI ≤4 for patients with Crohn's disease OR by partial Mayo score (3-point Mayo score) ≤1 with rectal bleeding subscore =0 for patients with ulcerative colitis AND no use of systemic steroids during the 6 months before screening
Patients with a previous diagnosis of Crohn's disease or Ulcerative colitis at least 3 months before screening
Patients with stable maintenance therapy for IBD, meaning a stable dose of mesalamine, immunosuppressants of biological drugs for at least 8 weeks before ESG (baseline).

Exclusion Criteria14

Active Helicobacter pylori infection, causing erosions or ulcers of the stomach or duodenum.
Organic or motility disorder of the stomach and / or esophagus
Previous bariatric surgery or any other type of surgery that causes alteration of the lumen of the esophagus, stomach and duodenum
Ongoing or active malignancy during the last 5 years.
Myocardial infarction during the past 6 months or/and heart failure class III or IV according to the New York Heart association's classification.
Drug or alcohol abuse
Bulimic or binge eating pattern
Uncontrolled thyroid disease
Pregnancy, breastfeeding
Psychiatric or cooperative problems or low compliance that is a contraindication from participating in the study.
Liver cirrhosis of any Child-Pugh stage or MELD> 15 Chronic Severe Renal Insufficiency (eGFR < 30 ml/min/1.73 m2 based on CKD-EPI equation)
Currently participating in other study, or previously participated in an experimental drugs trial within 30 days before or 5 half-life of the drug administered
Active IBD as defined by HBI >4 for patients with Crohn's disease OR by partial Mayo score >1 with rectal bleeding subscore ≥1 for patients with ulcerative colitis OR by the concomitant use of systemic steroids to control disease activity in both Crohn's disease and ulcerative colitis
Any health issue that might put the patient at risk if the treatment is performed, judged by the investigator.